| Characteristic | No. of patients, n (%) |
| Median age, years (range) | 68 (47-79) years |
| Sex | |
| Male | 7 (53.8) |
| Female | 6 (46.2) |
| PS | |
| 0 | 12 (92.3) |
| 1 | 1 (7.7) |
| No. of received pretreatment chemotherapies | |
| None | 10 (77.0) |
| One regimen | 2 (15.4) |
| Two regimens | 1 (7.7) |
| Metastatic site at the initiation of the study | |
| Regional LNs | 4 (30.8) |
| Distant LNs | 12 (92.3) |
| Lung | 3 (23.1) |
| Bone | 1 (7.7) |
| Liver | 3 (23.1) |
| HER2 status | |
| IHC 2 + with HER2 gene amplification | 6 (46.2) |
| IHC 3+ | 7 (53.8) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.